← GIP/GLP-1 & amylin agonists × all-cause mortality

SynthesisCardiovascular diabetology2026

Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.

Arveen Shokravi et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2026

Randomised comparison

Probably reduced cardiovascular events

−21%−31% to −9%

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.79, 95% CI 0.69–0.91

Randomised comparison

Probably reduced deaths

−21%−36% to −3%

Bigger than 6 in 10 for all-cause mortality

As reported

HR 0.79, 95% CI 0.64–0.97 · the paper's word: All-cause mortality

Randomised comparison

Probably reduced cardiovascular events

−23%−34% to −10%

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.77, 95% CI 0.66–0.90

Randomised comparison

Probably reduced deaths

−23%−39% to −3%

Bigger than 7 in 10 for all-cause mortality

As reported

HR 0.77, 95% CI 0.61–0.97 · the paper's word: All-cause mortality

+3 more in the walkthrough ↓

Seven numbers in the abstract

the abstract, start to end

… significantly reduced MACE (HR 0.79, 95% CI 0.69-0.91), CV mortality (HR 0.77, 95% CI 0.66-0.90), all-cause mortality (HR 0.74, 95% CI 0.65-0.83), non-fatal MI (HR 0.77, 95% CI 0.61-0.97), and non-fatal stroke (HR 0.79, 95% CI 0.64-0.97) compared to …

… reduced MACE compared to placebo (HR 0.81, 95% CI 0.70-0.94) and lixisenatide (HR 0.79, 95% CI 0.65-0.97).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.790.69–0.91
All-cause mortality
HR 0.790.64–0.97
Cardiovascular events
HR 0.770.66–0.90
All-cause mortality
HR 0.770.61–0.97
All-cause mortality
HR 0.740.65–0.83
Cardiovascular events
HR 0.810.70–0.94
Cardiovascular events
HR 0.790.65–0.97
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsCardiovascular eventsAll-cause mortality

GIP/GLP-1 & amylin agonists × all-cause mortalityhelps?one trial

unlikelylikely
0.35not counted

GIP/GLP-1 & amylin agonists × cardiovascular eventshelps?one trial

unlikelylikely
0.50not counted

GLP-1 receptor agonists × cardiovascular eventshelps?mixed

unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

3 papers cite it

2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 41761267